MD/PhD, Stanford University
I am a neurosurgery resident at the University of Toronto. In 2012 I left residency to pursue a PhD in developmental neurobiology at Stanford University. While at Stanford I entered a highly interdisciplinary project aimed at identifying novel drug targets for pediatric brain cancer. Ultimately, this led to a clinical trial for a promising new drug for the treatment of medulloblastoma, the most common pediatric brain cancer, which is planned to begin winter 2018.
Drug development is no longer just for Big Pharma. Researchers at Bio-X explain
Dec 21, 2018 11:03 am UTC| Insights & Views Health
I am a graduate student and resident in the field of neurosurgery and would like to share an unusual and very personal story of developing a drug. Developmental biologist Dr. Matthew Scott and I went from purely basic...
There’s an extra $1 billion on the table for NT schools. This could change lives if spent well
Political donations rules are finally in the spotlight – here’s what the government should do